Cleo Diagnostics (ASX:COV) Total Liabilities: A$1.14 Mil (As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.48
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Total Liabilities?

Cleo Diagnostics ASX:COV -3.03% 17 Total Liabilities is A$1.14 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Cleo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2025 was A$1.14 Mil.

Cleo Diagnostics's quarterly Total Liabilities increased from Dec. 2024 (A$0.45 Mil) to Jun. 2025 (A$1.10 Mil) and increased from Jun. 2025 (A$1.10 Mil) to Dec. 2025 (A$1.14 Mil).

Cleo Diagnostics's annual Total Liabilities declined from Jun. 2023 (A$2.02 Mil) to Jun. 2024 (A$0.49 Mil) but then increased from Jun. 2024 (A$0.49 Mil) to Jun. 2025 (A$1.10 Mil).

Cleo Diagnostics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Total Liabilities Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Total Liabilities
2.02 0.49 1.10

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial 0.20 0.49 0.45 1.10 1.14
ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cleo Diagnostics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.102+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.10

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=6.936-5.834
=1.10

Cleo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.135+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.14

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=9.961-8.825
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$1.14 Mil mean?
Cleo Diagnostics (ASX:COV) has a Total Liabilities of A$1.14 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Total Liabilities too high?
Cleo Diagnostics' current Total Liabilities is A$1.14 Mil. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Total Liabilities compare to ABT and SYK?
Cleo Diagnostics' Total Liabilities of A$1.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cleo Diagnostics and its competitors. Cleo Diagnostics's current Total Liabilities is A$1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Total Liabilities of A$1.14 Mil. The current Total Liabilities is A$1.14 Mil. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Total Liabilities is A$1.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price